# Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

> **NCT04377932** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 14 (actual)

## Conditions studied

- Liver Cancer
- Rhabdomyosarcoma
- Malignant Rhabdoid Tumor
- Liposarcoma
- Wilms Tumor
- Yolk Sac Tumor

## Interventions

- **GENETIC:** AGAR T cells

## Key facts

- **NCT ID:** NCT04377932
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-08
- **Primary completion:** 2024-08-17
- **Final completion:** 2040-08-26
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377932, "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04377932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*